We are international
• treatment options TEXT SIZE   
Novel Therapies

Novel therapies include treatments that has been shown to be effective for myeloma and those that have active clinical trials.
POMALYST® (pomalidomide) capsules
Pomalyst® is the newest oral immun­omodulatory drug (IMiD®). Approved by the FDA in 2013, Pomalyst is chemically related to thalidomide and lenalidomide, which was approved by the FDA in 2006, but Pomalyst has been enhanced to be more effective.
KYPROLIS™ (carfilzomib)
Kyprolis™ (carfilzomib) is a next-generation proteasome inhibitor. It is FDA-approved for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies, including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of the completion of the last therapy.

REVLIMID® (lenalidomide)
REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells.
THALOMID® (Thalidomide)
Helpful information about Thalidomide Therapy for patients and caregivers, including clinical trials with THALOMID®. Watch "Ask the Expert" videos from ASCO 2004 and the Lymphoma Myeloma Conference 2004.

VELCADE® (bortezomib) for Injection
VELCADE® is an antineoplastic agent available for intravenous injection (IV) use only. It has been approved by the FDA for the treatment of myeloma. Watch the "Ask the Expert" Videos from ASCO 2004 and Lymphoma Myeloma Conference 2004 on VELCADE® as treatment and in research.
DOXIL® is made of fat bubbles called liposomes that contain doxorubicin, a drug that has been used to treat cancer for over 20 years. In DOXIL, these liposomes are surrounded by a layer of hairlike strands made from polyethylene glycol.

Dexamethasone, an adrenal corticosteroid, is used to treat multiple myeloma.
MLN9708 (ixazomib) belongs to the same class of drugs as Velcade (bortezomib), called proteasome inhibitors, and it is being developed by Millennium Pharmaceuticals, the same company that developed Velcade.

Radiation Therapy
Radiation is often used for treatment of myeloma bone disease.